Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 FXR and PXR: potential therapeutic targets in cholestasis.

Literature DB >> 21801835

FXR and PXR: potential therapeutic targets in cholestasis.

Johan W Jonker¹, Christopher Liddle, Michael Downes.

Abstract

Cholestatic liver disorders encompass hepatobiliary diseases of diverse etiologies characterized by the accumulation of bile acids, bilirubin and cholesterol as the result of impaired secretion of bile. Members of the nuclear receptor (NR) family of ligand-modulated transcription factors are implicated in the adaptive response to cholestasis. NRs coordinately regulate bile acid and phospholipid transporter genes required for hepatobiliary transport, as well as the phases I and II metabolizing enzymes involved in processing of their substrates. In this review we will focus on FXR and PXR, two members of the NR family whose activities are regulated by bile acids. In addition, we also discuss the potential of pharmacological modulators of these receptors as novel therapies for cholestatic disorders.

Entities: CellLine Chemical Disease Gene Species

Mesh：

Substances：

Year: 2011 PMID： 21801835 PMCID： PMC4750880 DOI： 10.1016/j.jsbmb.2011.06.012

Source DB: PubMed Journal: J Steroid Biochem Mol Biol ISSN： 0960-0760 Impact factor: 4.292

138 in total

Review 1. Drug-induced cholestasis.

Authors: S Chitturi; G C Farrell
Journal: Semin Gastrointest Dis Date: 2001-04

2. Mice overexpressing hepatic Abcb11 rapidly develop cholesterol gallstones.

Authors: Anne Henkel; Zhixin Wei; David E Cohen; Richard M Green
Journal: Mamm Genome Date: 2005-12-08 Impact factor: 2.957

3. The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution.

Authors: S A Jones; L B Moore; J L Shenk; G B Wisely; G A Hamilton; D D McKee; N C Tomkinson; E L LeCluyse; M H Lambert; T M Willson; S A Kliewer; J T Moore
Journal: Mol Endocrinol Date: 2000-01

Review 4. Pharmaceutical use of mouse models humanized for the xenobiotic receptor.

Authors: Wen Xie; Ronald M Evans
Journal: Drug Discov Today Date: 2002-05-01 Impact factor: 7.851

5. Discovery of sulfated sterols from marine invertebrates as a new class of marine natural antagonists of farnesoid-X-receptor.

Authors: Valentina Sepe; Giuseppe Bifulco; Barbara Renga; Claudio D'Amore; Stefano Fiorucci; Angela Zampella
Journal: J Med Chem Date: 2011-02-10 Impact factor: 7.446

6. Bile acid signaling pathways increase stability of Small Heterodimer Partner (SHP) by inhibiting ubiquitin-proteasomal degradation.

Authors: Ji Miao; Zhen Xiao; Deepthi Kanamaluru; Gyesik Min; Peter M Yau; Timothy D Veenstra; Ewa Ellis; Steve Strom; Kelly Suino-Powell; H Eric Xu; Jongsook Kim Kemper
Journal: Genes Dev Date: 2009-04-15 Impact factor: 11.361

7. Levels of plasma membrane expression in progressive and benign mutations of the bile salt export pump (Bsep/Abcb11) correlate with severity of cholestatic diseases.

Authors: Ping Lam; Claire L Pearson; Carol J Soroka; Shuhua Xu; Albert Mennone; James L Boyer
Journal: Am J Physiol Cell Physiol Date: 2007-09-13 Impact factor: 4.249

8. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.

Authors: Keith D Lindor; Kris V Kowdley; Velimir A C Luketic; M Edwyn Harrison; Timothy McCashland; Alex S Befeler; Denise Harnois; Roberta Jorgensen; Jan Petz; Jill Keach; Jody Mooney; Carol Sargeant; Julie Braaten; Tamara Bernard; Debra King; Ellen Miceli; Jeff Schmoll; Tanya Hoskin; Prabin Thapa; Felicity Enders
Journal: Hepatology Date: 2009-09 Impact factor: 17.425

9. The human MDR3 P-glycoprotein promotes translocation of phosphatidylcholine through the plasma membrane of fibroblasts from transgenic mice.

Authors: A J Smith; J L Timmermans-Hereijgers; B Roelofsen; K W Wirtz; W J van Blitterswijk; J J Smit; A H Schinkel; P Borst
Journal: FEBS Lett Date: 1994-11-14 Impact factor: 4.124

10. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis.

Authors: Serkan Kir; Sara A Beddow; Varman T Samuel; Paul Miller; Stephen F Previs; Kelly Suino-Powell; H Eric Xu; Gerald I Shulman; Steven A Kliewer; David J Mangelsdorf
Journal: Science Date: 2011-03-25 Impact factor: 47.728

44 in total

1. Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis.

Authors: B C Ferslew; C K Johnston; E Tsakalozou; A S Bridges; M F Paine; W Jia; P W Stewart; A S Barritt; K L R Brouwer
Journal: Clin Pharmacol Ther Date: 2015-03-15 Impact factor: 6.875

2. Oral administration of oleanolic acid, isolated from Swertia mussotii Franch, attenuates liver injury, inflammation, and cholestasis in bile duct-ligated rats.

Authors: Jin Chai; Xiaohuang Du; Sheng Chen; XinChan Feng; Ying Cheng; Liangjun Zhang; Yu Gao; Shaoxue Li; Xiaochong He; Rongquan Wang; Xiangdong Zhou; Yong Yang; Weizao Luo; Wensheng Chen
Journal: Int J Clin Exp Med Date: 2015-02-15

3. [Protective effect of emodin pretreatment in young rats with intrahepatic cholestasis].

Authors: Xiao-Li Xiong; Su-Qi Yan; Huan Qin; Li-Shan Zhou; Ling-Ling Zhang; Zhi-Xia Jiang; Yan Ding
Journal: Zhongguo Dang Dai Er Ke Za Zhi Date: 2016-02

Review 4. An updated review on drug-induced cholestasis: mechanisms and investigation of physicochemical properties and pharmacokinetic parameters.

Authors: Kyunghee Yang; Kathleen Köck; Alexander Sedykh; Alexander Tropsha; Kim L R Brouwer
Journal: J Pharm Sci Date: 2013-05-07 Impact factor: 3.534

5. Swertianlarin, isolated from Swertia mussotii Franch, increases detoxification enzymes and efflux transporters expression in rats.

Authors: Xin-Chan Feng; Xiaohuang Du; Sheng Chen; Dongmei Yue; Ying Cheng; Liangjun Zhang; Yu Gao; Shaoxue Li; Lei Chen; Zhihong Peng; Yong Yang; Weizao Luo; Rongquan Wang; Wensheng Chen; Jin Chai
Journal: Int J Clin Exp Pathol Date: 2015-01-01